Literature DB >> 14614314

Clinicopathologic and molecular features of Hodgkin's lymphoma.

Anas Younes1, Antonio Carbone.   

Abstract

Hodgkin's lymphoma is a relatively uncommon malignancy that predominantly effects young adults. It became the first human cancer to be cured with combination chemotherapy. Unfortunately, many cured patients do not live their expected lifespan because of long-term lethal effects of therapy. Novel treatment strategies based on our understanding of Hodgkin's lymphoma biology are currently being explored to maintain the high cure rate without the added treatment related toxicity.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14614314     DOI: 10.4161/cbt.2.5.510

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  1 in total

1.  ABVD plus rituximab versus ABVD alone for advanced stage, high-risk classical Hodgkin lymphoma: a randomized phase 2 study.

Authors:  Paolo Strati; Michelle A Fanale; Yasuhiro Oki; Francesco Turturro; Luis E Fayad; Nancy L Bartlett; Douglas E Gladstone; Yvette L Kasamon; Carol S Portlock; Wyndham H Wilson; Andre Goy; Anas Younes; Hun Ju Lee
Journal:  Haematologica       Date:  2018-09-06       Impact factor: 9.941

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.